据公开资料，姜伟主导研发肿瘤诊疗大模型，其质子治疗垂直大模型已成行业标杆；推动搭建MAICOP 医疗人工智能云平台，突破多模态影像融合技术，适配PET-CT、MR、CT等各类设备，并带领团队拿 下多个"医学图像处理软件"医疗器械注册证，实现技术应用落地。这些成果为集团开辟第二增长曲线奠 定基础。 分析人士指出："美中嘉和此时任命姜伟为总裁，意图非常明显。在DRG/DIP 支付改革持续深化的行业 背景下，传统医院单纯靠扩大规模的增长模式已遇瓶颈。董事会选择一位懂资本、懂医疗、懂AI的'少 壮派'掌舵，显然是希望通过技术手段提升诊疗效率，挖掘数据价值，寻找第二增长曲线。" 战略变阵：AI不再是"锦上添花"，而是"核心引擎" （1月12日），港股上市公司美中嘉和（02453.HK）发布人事公告。公告显示，付骁女士因到退休年龄 和集团职务调整退任总裁一职，原美中嘉和AI业务板块负责人姜伟先生正式接棒，出任集团新任总 裁。 作为国内领先的肿瘤医疗集团，美中嘉和此次将帅印交给一位具有深厚投行背景且长期掌舵AI业务的 高管，被资本市场视为公司从"传统医疗服务"向"智能化肿瘤诊疗生态"全面转型的关键信号。 "跨界"挂帅：从顶 ...

专家表示，随着我国经济社会不断发展，科研体制不断完善，我国癌症防治工作稳步发展。部分瘤种像乳腺癌、前列腺癌的五年生存率已经达到可喜的90% 以上。抗肿瘤创新药物和疗法不断涌现，推动着肿瘤治疗逐步进入慢病管理时代，肿瘤防治正朝着规范化、精准化、创新化方向发展。同时，癌症防治是健 康中国建设的重要课题，通过内科、外科、放疗科等多学科专家联合会诊的多学科协作模式已成为肿瘤治疗的主流趋势，今后，更需锚定群众健康需求，破 解现实挑战，凝聚多方合力，推进防治工作高质量发展。 交流会现场邀请了多位中青年医生入驻"人民好医生・金山茶花计划"临床科研创新中青年专家库。中青年医生代表表示，期盼能有更多投身临床科研与创新 探索的机会，学习借鉴国际前沿的医学技术与理念，共同助力肿瘤防控能力提升。（宋一诺） 在12月21日召开的2025"人民好医生·金山茶花计划"总结交流会上，肺癌、肝胆肿瘤、胃癌、食管癌、乳腺癌、鼻咽癌等领域专家探讨盘点了2025年我国癌 症防控新进展，共同探讨癌症防控新进展，助力推进癌症防控事业高质量发展。 2020年，人民网、人民健康联合肿瘤防控领域权威的专家学者以及战略支持方共同启动了"人民好医生·金山茶花计划 ...

Core Insights - The "People's Good Doctor Jinshan Camellia Plan" conference highlighted advancements in cancer prevention and control, focusing on high-quality development in the field [1] Group 1: Cancer Treatment Advances - Hepatobiliary tumor treatment has entered an immune-dominant phase, significantly extending patient survival and creating curative opportunities for inoperable tumors [1] - Lung cancer patients have seen improved survival rates due to the promotion of precision diagnosis and treatment, with breakthroughs in small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) [2] - Innovative drugs and treatment strategies in esophageal and gastric cancers have led to significant clinical advancements, although challenges in standardization and precision screening remain [2] Group 2: Multidisciplinary Collaboration - A multidisciplinary collaboration model is becoming mainstream in cancer treatment, allowing for personalized treatment plans through joint consultations among various specialists [4] - There is a need for improved management of patient follow-ups and a more balanced regional development in cancer prevention and treatment [4] Group 3: Emerging Treatment Modalities - Immunotherapy combined with chemotherapy has become a first-line treatment for advanced nasopharyngeal carcinoma, with ongoing exploration of different intervention models [3] - The application of CAR-T cell therapy and targeted drugs has provided long-term survival opportunities for previously hard-to-treat hematological cancer patients [3] Group 4: Future Directions - Continuous innovation in clinical research and acceleration of new treatment technologies are essential for enhancing cancer prevention and treatment systems [5] - The focus should be on early screening, diagnosis, and treatment management to provide patients with better survival prospects [5]

Core Insights - Cancer remains a significant threat to public health and hinders the improvement of residents' health levels [1] - The "People's Good Doctor · Jinshan Camellia Plan" aims to promote high-quality cancer prevention and control through clinical research and innovation [3] Group 1: Cancer Treatment Advances - Current cancer treatment has entered a new era characterized by precision, individualization, and multidisciplinary collaboration [3] - Immunotherapy, in conjunction with targeted and interventional therapies, has significantly extended patient survival rates and created curative opportunities for some inoperable tumors [1] - The promotion of precision diagnosis and treatment, along with the application of targeted and immunotherapy, has effectively improved the survival and quality of life for lung cancer patients [1] Group 2: Future Directions in Cancer Care - Future cancer treatment should focus on precise stratification, mechanism collaboration, and comprehensive management throughout the disease course [1] - There is a need to enhance early screening and diagnosis for high-risk populations, optimize combined treatment plans, and encourage young doctors to engage in clinical research and innovation [1] - The cancer prevention and treatment system should be improved to achieve comprehensive management of early screening, diagnosis, and treatment, providing patients with greater hope for survival [3]

癌症是危害公众生命健康、制约居民健康水平提升的重要因素。12月21日，2025"人民好医生·金山茶花计划"总结交流在北京举行。现场汇集了肺癌、 肝胆肿瘤、胃癌、食管癌、乳腺癌、妇科肿瘤、泌尿肿瘤、淋巴瘤、鼻咽癌等领域专家，共同探讨癌症防控新进展，助力推进癌症防控事业高质量发展。 立足健康需求 共商癌症防治对策 癌症防治是健康中国建设的重要课题，需锚定群众健康需求，破解现实挑战，凝聚多方合力，推进高质量发展。 中国科学院院士、复旦大学附属中山医院名誉院长樊嘉分享了对于肝胆肿瘤治疗的一些观察与思考。他说，当前肝胆肿瘤治疗已迈入免疫主导阶段，免 疫治疗与靶向、介入治疗的协同联动，显著延长了患者生存期，还为部分不可切除肿瘤创造根治机会。2025年，国内外权威指南修订、国内多项专家共识出 台，进一步推动肝胆肿瘤诊疗从"经验型"向"循证型"转变。樊嘉建议，未来诊疗需向精准分层、机制协同、全病程管理深化，直面百姓健康关切，既要强化 高危人群早筛早诊与科普宣传，优化联合治疗方案，也要鼓励中青年医生投身临床科研创新、紧盯国际前沿。随着人才成长与技术进步，我国肝胆肿瘤防治 事业将实现更高质量发展。 目前，肿瘤治疗已迈入精准化、个 ...

Core Insights - Cancer remains a significant global public health challenge, with the WHO reporting 10 million deaths in 2020, accounting for 1 in 6 deaths globally. Without urgent action, cancer deaths could exceed 18 million by 2050 [1][2] - China has emerged as a key player in cancer research, with a record number of studies presented at major international oncology conferences, indicating its growing influence in the field [1][2] - The introduction of 114 new drugs in the 2025 National Basic Medical Insurance Directory, including 36 cancer drugs, expands treatment options for cancer patients [2] Group 1: Cancer Statistics and Projections - The global burden of cancer is expected to rise, with new cases projected to reach 28.4 million by 2040, a 47% increase from 19.3 million in 2020 [2] - The concept of "5-year survival rate" may evolve to "10-year survival rate," with predictions suggesting a 95% survival rate by 2040 and the potential for cancer to be managed as a chronic disease by 2050 [5] Group 2: Factors Influencing Cancer Development - Five main factors contributing to cancer include external triggers, infection-related factors, hormonal/receptor imbalances, lifestyle-related factors, and psychological/immune-related triggers [3] - The essence of cancer is a disruption in the body's regulatory mechanisms, leading to uncontrolled cell proliferation [3] Group 3: Innovations and Future Directions - Advances in technology, including digital communication, genomics, and artificial intelligence, are expected to enhance cancer survival rates and improve access to quality healthcare [4][7] - The establishment of new cancer classification standards and a focus on integrated treatment approaches are anticipated to transform cancer management and clinical outcomes [4] Group 4: Challenges in Cancer Treatment - The transition from fragmented to integrated treatment poses challenges, including the need for updated knowledge among healthcare professionals and the development of innovative diagnostic and treatment technologies [6][8] - Early diagnosis is critical for improving treatment success rates, with AI playing a role in enhancing the identification of high-risk populations [6] Group 5: Immunotherapy Growth - Immunotherapy has emerged as a significant growth area in cancer treatment, with a projected global market size of $84.9 billion by 2030, driven by advancements in CAR-T, TCR-T, and NK cell therapies [7] - Despite its potential, challenges remain in biomarker selection, toxicity management, and cost control, with breakthroughs expected within the next 25 years [7][8]

证券之星消息，12月9日南向资金增持1.02万股佰泽医疗（02609.HK）。近5个交易日中，获南向资金减 持的有1天，累计净减持38.28万股。近20个交易日中，获南向资金减持的有10天，累计净减持200.94万 股。截至目前，南向资金持有佰泽医疗（02609.HK）6247.14万股，占公司已发行普通股的4.73%。 佰泽医疗集团是一家主要从事投资及提供医疗相关服务的肿瘤医疗公司。该公司在肿瘤全周期医疗服务 领域提供服务，包括筛查、诊断、治疗及康复。该公司主要从事医院业务、医院管理服务、供应药品、 医疗设备及耗材及其他业务。该公司业务包括对患者开展肿瘤诊断、肿瘤治疗、肿瘤康复及临终关怀 等，以及对其他潜在健康人群开展的早癌筛查、肿瘤疫苗接种、健康管理服务。该公司主要在中国市场 开展业务。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 ...

Core Viewpoint - Meizhong Jiahe Medical Technology Development Group has been approved to enter the "Hong Kong-Macao Drug and Medical Device Access" designated medical institution list, positioning itself as a key beneficiary of the policy and providing clear growth opportunities for investors [1][3]. Group 1: Company Developments - The approval allows Guangzhou Taihe Tumor Hospital to import and use urgently needed drugs and advanced medical devices that are already listed in Hong Kong and Macao but not yet approved in mainland China [1]. - The hospital can now introduce innovative drugs and medical devices in the oncology field, enhancing its competitive advantage and broadening its business scope [1][2]. Group 2: Industry Implications - The "Hong Kong-Macao Drug and Medical Device Access" initiative aims to improve the quality of medical services and align domestic treatments with international standards, particularly in oncology [2][3]. - The initiative is expected to reduce the treatment time gap between mainland China and international markets, particularly for diseases like breast cancer and lung cancer, thereby enhancing patient treatment options [2]. - The increased accessibility of cross-border medical resources will likely attract more patients to hospitals with such capabilities, creating a "regional treatment center" effect and increasing overall service intensity [2][3].

Core Viewpoint - The stock of Meizhong Jiahe (02453) opened over 6% higher following the approval of its subsidiary, Guangzhou Taihe Oncology Hospital, to enter the "Hong Kong-Macao Drug and Medical Device Pass" designated medical institution list [1] Group 1: Company Developments - Meizhong Jiahe's stock rose by 6.12%, reaching HKD 2.08, with a trading volume of HKD 100,700 [1] - The approval allows Guangzhou Taihe Oncology Hospital to import and use urgently needed drugs and advanced medical devices that are already listed in Hong Kong and Macao but not yet approved in mainland China [1] - This qualification positions the company as a specialized oncology medical institution with the capability to utilize innovative drugs and medical devices, enhancing its competitive advantage in the oncology field [1] Group 2: Industry Context - The "Hong Kong-Macao Drug and Medical Device Pass" is a key initiative under the "Guangdong-Hong Kong-Macao Greater Bay Area Drug and Medical Device Regulatory Innovation Development Work Plan" [1] - Designated medical institutions in the Greater Bay Area can leverage special pharmaceutical policies, allowing them to access advanced medical solutions [1] - The initiative aims to broaden the business scope of qualified institutions and provide urgently needed medications to more oncology patients, thereby strengthening the overall competitive landscape in the oncology medical sector [1]

热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易 美中嘉和（02453）早盘高开，截至发稿，股价上涨8.67%，报2.13港元，成交额66.46万港元。 美中嘉和发布公告，公司子公司广州泰和肿瘤医院于2025年12月8日，获广东省卫生健康委员会与广东 省药品监督管理局批准进入粤港澳大湾区"港澳药械通"指定医疗机构名单。 "港澳药械通"是《粤港澳大湾区药品医疗器械监管创新发展工作方案》的核心落地举措，进入名单的粤 港澳大湾区的指定医疗机构，可经审批进口使用粤港澳大湾区专项医药政策，允许指定医疗机构经审批 使用港澳已上市的临床急需药品及具有先进性的医疗器械。 客户端 美中嘉和（02453）早盘高开，截至发稿，股价上涨8.67%，报2.13港元，成交额66.46万港元。 美中嘉和发布公告，公司子公司广州泰和肿瘤医院于2025年12月8日，获广东省卫生健康委员会与广东 省药品监督管理局批准进入粤港澳大湾区"港澳药械通"指定医疗机构名单。 "港澳药械通"是《粤港澳大湾区药品医疗器械监管创新发展工作方案》的核心落地举措，进入名单的粤 港澳大湾区的指定医疗机构，可经审批进口使用粤港澳大湾区专项医药政策，允许指定医疗 ...